BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1708953)

  • 1. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia.
    Fuggetta MP; D'Onofrio C; Bonmassar E
    Ann Ist Super Sanita; 1990; 26(3-4):385-95. PubMed ID: 1708953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
    Yokota S; Hara H; Luo Y; Seon BK
    Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of biological response modifiers on lung natural killer activity.
    Lauzon W; Lemaire I
    Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
    Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumoricidal biological response modifiers (BRM)].
    Niitsu Y; Kohgo Y; Watanabe N
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of immunity and antitumor drugs against cancer. II. In vitro studies with cis-diamminedichloroplatinum in a human leukemia system.
    De Filippi R; Fuggetta MP; Ricci F; Marini S; Caliendo R; Giuliani A
    Chemioterapia; 1987 Dec; 6(6):410-6. PubMed ID: 2449291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferons in hemato-cancerology].
    Boiron M
    Nouv Rev Fr Hematol (1978); 1987; 29(1):49-55. PubMed ID: 2438645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
    Leon JA; Mesa-Tejada R; Gutierrez MC; Estabrook A; Greiner JW; Schlom J; Fisher PB
    Anticancer Res; 1989; 9(6):1639-47. PubMed ID: 2516715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential interference of alpha, beta or gamma interferons with HTLV-I integration and expression in vitro.
    D'Onofrio C; Alvino E; Peci E; CaliĆ² R; Bonmassar E
    Ann Ist Super Sanita; 1991; 27(1):127-32. PubMed ID: 1958020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells.
    De Filippi R; Prete SP; Giuliani A; Silvi E; Yamaue H; Nieroda CA; Greiner JW; De Vecchis L; Bonmassar E
    Anticancer Res; 1994; 14(5A):1767-73. PubMed ID: 7847809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of biological activity of interferons.
    Battistini A; Affabris E; Fiorucci G; Coccia EM; Romeo G; Marziali G; Rossi GB
    Ann Ist Super Sanita; 1990; 26(3-4):227-53. PubMed ID: 1708952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human natural killer activity in selected test systems and tissue compartments: natural killer cell modulation by biological response modifiers].
    Klappacher G
    Wien Klin Wochenschr; 1988 Nov; 100(22):743-6. PubMed ID: 3149079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human natural cytotoxicity by IgG. III. Interaction between negative regulation by monomeric IgG and positive regulation by interferons of different types.
    Sulica A; Gherman M; Manciulea M; Galatiuc C; Herberman RB
    Nat Immun Cell Growth Regul; 1989; 8(5):266-78. PubMed ID: 2480519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.
    Sidky YA; Borden EC
    Cancer Res; 1987 Oct; 47(19):5155-61. PubMed ID: 2441862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of in vitro hyperthermia on natural killer activity from lung, blood and spleen.
    Yang H; Mitchel R; Lemaire I
    J Clin Lab Immunol; 1990 Jul; 32(3):117-22. PubMed ID: 1726330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
    Schaber JD; Fang H; Xu J; Grimley PM; Rui H
    Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons in oncology.
    Woll PJ; Pettengell R
    Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.